Safety
Tirzepatide, Pregnancy, and Contraception
Tirzepatide is not recommended during pregnancy, and weight loss during pregnancy is not advised. Labelling includes a specific consideration for people using oral contraceptives, because delayed gastric emptying can affect their absorption around dose initiation and escalation. Anyone pregnant, planning pregnancy, or breastfeeding should discuss this with a prescriber before starting.
Key takeaways
- Tirzepatide is not recommended in pregnancy, and weight loss in pregnancy is not advised.
- Labelling includes specific guidance regarding oral contraceptive absorption.
- Delayed gastric emptying can affect oral contraceptive reliability around dose changes.
- Improved fertility can accompany weight reduction, making contraception planning relevant.
- Pregnancy planning and breastfeeding require a prescriber conversation before starting.
| Pregnancy | Not recommended |
|---|---|
| Weight loss in pregnancy | Not advised |
| Oral contraceptives | Labelling includes specific guidance on absorption |
| Fertility | Can improve with weight reduction |
| Breastfeeding | Discuss with a prescriber |
| Planning pregnancy | Discuss timing with a prescriber before starting |
Why does tirzepatide affect oral contraception?
Because slowed gastric emptying can alter how an oral contraceptive is absorbed, particularly when tirzepatide is started and at each dose increase. Product labelling addresses this specifically and describes precautions. This is one of the most consequential practical details about the drug and is frequently omitted from telehealth intake conversations.
The specific precaution and its duration are labelling matters to discuss with your prescriber or pharmacist rather than to generalise from a website.
Why does fertility change matter here?
Weight reduction can restore ovulation in people who were not ovulating regularly, which means fertility may increase during treatment — sometimes unexpectedly. Combined with the contraceptive absorption issue, this makes contraception planning a genuine part of starting the medication rather than an afterthought.
What the evidence shows
- Labelled guidance regarding pregnancy and oral contraceptive absorption.
- The relationship between weight reduction and restored fertility.
What the evidence does not show
- A specific contraceptive protocol — that is a labelling and prescriber matter.
- Safety data supporting use during pregnancy.
Related: Contraindications · Eligibility
How large is the effect across the verified trials?
| Trial arm | Point estimate | Range | N |
|---|---|---|---|
| SURMOUNT-1 · 15 mg | 20.9% | 19.5% to 22.3% | 2,539 |
| SURMOUNT-1 · 10 mg | 19.5% | 18.2% to 20.8% | 2,539 |
| SURMOUNT-1 · 5 mg | 15.0% | 13.8% to 16.2% | 2,539 |
| SURMOUNT-2 · 15 mg | 14.7% | 13.4% to 16.0% | 938 |
| SURMOUNT-2 · 10 mg | 12.8% | 11.5% to 14.1% | 938 |
| SURMOUNT-1 · placebo | 3.1% | 2.3% to 3.9% | 2,539 |
When was each piece of this evidence established?
| Date | Event |
|---|---|
| May 2022 | Tirzepatide approved as Mounjaro for type 2 diabetes |
| Jun 2022 | SURMOUNT-1 published in the New England Journal of Medicine |
| Jul 2023 | SURMOUNT-2 published in the Lancet |
| Nov 2023 | Tirzepatide approved as Zepbound for chronic weight management |
| Dec 2023 | SURMOUNT-4 withdrawal results published in JAMA |
| Jun 2024 | SURMOUNT-OSA published; obstructive sleep apnoea evidence established |
| May 2025 | SURMOUNT-5 head-to-head against semaglutide published in NEJM |
What does this page cover, and what does it deliberately leave out?
This page addresses Label guidance and reproductive considerations and contraception, organised around the primary question of tirzepatide pregnancy. Each of those elements is treated separately below rather than blended, because they carry different evidence weights and a reader is entitled to know which parts rest on randomised data and which rest on a captured commercial claim or a regulatory document.
| Element | Treatment here | Evidence basis |
|---|---|---|
| Label guidance | Covered on this page | Primary evidence |
| Reproductive considerations and contraception | Covered on this page | Primary evidence |
| Individualized clinical instruction | Deliberately not covered | Belongs with a prescriber who knows your history |
What are the limits of what this page can tell you?
Every page on this site rests on a specific clinical evidence, and that record has boundaries worth stating plainly rather than leaving a reader to discover them. The limitations below are specific to the material presented above.
- The evidence here describes groups, populations, or captured records — it does not describe you, and no page can substitute for a prescriber who knows your history.
- Figures carry the date on which they were verified. In a market where terms change frequently, an undated figure functions as a claim about the present that nobody has checked.
- Elements marked Verification Pending are genuinely unknown to this publication rather than merely omitted for brevity, and should not be inferred from surrounding content.
- Where a source conflicts with another, this site shows the conflict rather than resolving it, which means some questions are left open on purpose.
What would change the conclusion on this page?
The following would trigger a revision to this page, recorded in its change history:
- New primary evidence bearing directly on tirzepatide pregnancy.
- A change to FDA labelling affecting any statement made above.
- A verified correction submitted through the corrections process and accepted on the evidence.
- A material change to a captured record, including a price, term, or regulatory status.
- Completion of a verification currently marked pending, which would replace a gap with a stated fact.
Frequently asked questions
Can I take tirzepatide while pregnant?
It is not recommended in pregnancy, and weight loss during pregnancy is not advised.
Does tirzepatide affect birth control?
Labelling includes specific guidance because delayed gastric emptying can affect oral contraceptive absorption, particularly around dose changes. Discuss with your prescriber.
Can it make me more fertile?
Weight reduction can restore regular ovulation, so fertility may increase during treatment.
What if I want to conceive?
Discuss timing with your prescriber before starting or continuing.
Is it safe while breastfeeding?
That requires a prescriber discussion; this site does not make that determination.
Change history
| Date | Change |
|---|---|
| 2026-07-22 | Page published with current dataset snapshot. |
Dates change only for substantive edits, never for cosmetic changes. Corrections: corrections policy.